RxDoctor Payments Data

Baljeet Mahal, MD

Cardiology · Cumberland, MDNPI 1467405514

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.3% of the total across 13 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Johnson & Johnson at 47.2% of the total. That places this record below the midpoint for cardiology clinicians in MD, where the typical reported total is $21.

$181in general payments, 2019–2025

Across 13 payments — averaging $13.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$86
  • E.r. Squibb & Sons, L.L.C.$44
  • Pfizer$28
  • AstraZeneca$12
  • Novartis$11

What the payments were for

  • Food & beverage$16993%
  • Education$127%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$181 in reported general payments places this provider in the 50th percentile of 44 cardiology providers in Maryland.

See all cardiology providers in Maryland

Medicare billing

Part B allowed, 2024
$184,516
Medicare patients
536
Services billed
2,253

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban112$106,948
XareltoRivaroxaban51$47,810
EntrestoSacubitril/Valsartan12$24,063
Metoprolol Succinate117$1,686
Isosorbide Mononitrate ErIsosorbide Mononitrate50$539
Atorvastatin Calcium47$502
ClopidogrelClopidogrel Bisulfate34$491
Metoprolol Tartrate61$482
Rosuvastatin Calcium25$449
Amlodipine Besylate42$444
Carvedilol61$444
Pantoprazole Sodium16$280
Spironolactone29$279
Ranolazine ErRanolazine12$267
Warfarin Sodium19$243

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$28$106,948112 claims
Johnson & JohnsonXarelto$86$47,81051 claims
NovartisEntresto$11$24,06312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 44 cardiology providers in Maryland.

Other cardiology in Cumberland

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →